Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Katia Beider, Noy Sharvit Boaron, Valeria Voevoda, Olga Ostrovsky, Ivetta Danylesko, Avichai Shimoni, Amnon Peled, Arnon Nagler

Blood (2022) 140 (Supplement 1): 5969–5970.

https://doi.org/10.1182/blood-2022-164646

Published: 2022

Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Michal Abraham, Inbal Mishalian, Abi Vainstein, Liron Shemesh-Darvish, Ella Sorani, Orly Eizenberg, Amnon Peled

Blood (2021) 138 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2021-147142

Published: 2021

Journal Articles

Transcriptional and Metabolic Profiling of Nicotinamide-Enhanced Natural Killer (NAM-NK) Cells (GDA-201)

Blood (2021) 138 (Supplement 1): 4791.

https://doi.org/10.1182/blood-2021-149468

Published: 2021

Journal Articles

Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma

Evgenia Rosenberg, Valeria Voevoda, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Amnon Peled, Arnon Nagler, Katia Beider

Blood (2021) 138 (Supplement 1): 1195.

https://doi.org/10.1182/blood-2021-149372

Published: 2021

Journal Articles

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Ewa Cendrowicz, PhD, Lisa Jacob, Shirley Greenwald, Ami Tamir, Yosi Gozlan, Gerwin Huls, MD PhD, Adam Foley-Comer, Yaron Pereg, Ayelet Chajut, Amnon Peled, PhD, Edwin Bremer, PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140280

Published: 2020

Journal Articles

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

Tracey Lodie, PhD, Julian Adams, PhD, Dima Yackoubov, Msc, Yair Steinhardt, MSc, Dorit Ashengrau, Adi Bitansky, Alina Maliutina, Sherry Cohen, Boaz Buhenvald, PhD, Moshe Shahor, PhD, Nathan Dinowitz, PhD, Vered Caspi, PhD, Amnon Peled, PhD, Tony Peled, MSc

Blood (2019) 134 (Supplement_1): 3718.

https://doi.org/10.1182/blood-2019-131124

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

Shoshi Tessler, PhD, Inbal Mishalian, PhD, Ronny Peri-Naor, PhD, Stela Gengrinovitch, PhD, Raphael Mayer, PhD, Ruth Ben Yakar, PhD, Amnon Peled, Liat Flaishon, PhD MD

Blood (2018) 132 (Supplement 1): 1451.

https://doi.org/10.1182/blood-2018-99-112092

Published: 2018

Journal Articles

Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs)

Katia Beider, Evgenia Rosenberg, Valeria Voevoda, Hanna Bitner, Yaarit Sirovsky, Hila Magen, MD, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2018-99-114652

Published: 2018

Journal Articles

Brief Ex Vivo Incubation with Fas Ligand Selectively Depletes Alloreactive T Cells and Antigen Presenting Cells from Stem Cell Grafts

Hilit Levy-Barazany, PhD, Liat Pinkas, PhD, Galina Rodionov, Nitzan Marelly, Michal Tzadok, Hila Wildbaum, Tamar Katz, PhD, Ronit Bakimer, PhD, Shai Yarkoni, MD PhD, Amnon Peled, Jerry Stein, MD, Tsila Zuckerman, MD

Blood (2018) 132 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2018-99-117920

Published: 2018

Journal Articles

NK cell destiny after haploSCT with PT-Cy

Amnon Peled, Arnon Nagler

Blood (2018) 131 (2): 161–162.

https://doi.org/10.1182/blood-2017-10-811117

Published: 2018

Journal Articles

Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma

Katia Beider, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Yaarit Sirovsky, Hila Magen, MD, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Zohar Bromberg, PhD, Amnon Peled, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 804.

https://doi.org/10.1182/blood.V130.Suppl_1.804.804

Published: 2017

Journal Articles

Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-Applicable Method for NK Expansion

Tony Peled, Guy Brachya, Nurit Persi, Chana Lador, Esti Olesinski, Efrat Landau, Einat Galamidi, Amnon Peled, Jeffrey S. Miller, MD, Veronika Bachanova, MD PhD

Blood (2017) 130 (Supplement 1): 657.

https://doi.org/10.1182/blood.V130.Suppl_1.657.657

Published: 2017

Journal Articles

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

Michal Abraham, PhD, Galia Oberkovitz, PhD, Baruch Bulvik, Klein Shiri, Hanna Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, MD, Abi Vainstein, MD, Eyal Benami, Rotem Golan, Eithan Galun, Yoseph Caraco, Reuven Or, MD, Amnon Peled

Blood (2017) 130 (Supplement 1): 660.

https://doi.org/10.1182/blood.V130.Suppl_1.660.660

Published: 2017

Journal Articles

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

Blood (2016) 128 (22): 2745.

https://doi.org/10.1182/blood.V128.22.2745.2745

Published: 2016

Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

Michal Abraham, PhD, Shiri Klein, Baruch Bulvik, Hanna Wald, Dvora Holam, Lola Weiss, Katia Beider, PhD, Orly Eizenberg, Ori Wald, MD PhD, Abraham Avigdor, MD, Ohad Benjamini, MD, Eithan Galun, MD, Arnon Nagler, Yaron Pereg, PhD, Amnon Peled, PhD

Blood (2016) 128 (22): 767.

https://doi.org/10.1182/blood.V128.22.767.767

Published: 2016

Journal Articles

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

Katia Beider, PhD, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Hila Magen, MD, Olga Ostrovsky, PhD, Merav Leiba, MD, Noya Shilo, MD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, PhD, Arnon Nagler

Blood (2016) 128 (22): 891.

https://doi.org/10.1182/blood.V128.22.891.891

Published: 2016

Journal Articles

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

Blood (2015) 126 (23): 2546.

https://doi.org/10.1182/blood.V126.23.2546.2546

Published: 2015

Journal Articles

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

Katia Beider, PhD, Evgenia Rosenberg, Hanna Bitner, Merav Leiba, MD, Maya Koren-Michowitz, MD, Michal Abraham, PhD, Shiri Klein, Hanna Wald, Avichai Shimoni, MD, Amnon Peled, PhD, Arnon Nagler, MD

Blood (2014) 124 (21): 4707.

https://doi.org/10.1182/blood.V124.21.4707.4707

Published: 2014

Journal Articles

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

Gautam Borthakur, MD, Arnon Nagler, MD, Yishai Ofran, MD, Jacob M. Rowe, MD, Jessica K. Altman, MD, Olga Frankfurt, MD, Martin S. Tallman, MD, Irit Avivi, Amnon Peled, PhD, Yaron Pereg, PhD, Adam Foley-Comer, MD, Lena Russovsky, BS, Arnon Aharon, MD, Teresa McQueen, BS, Naveen Pemmaraju, MD, Carlos E. Bueso-Ramos, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 950.

https://doi.org/10.1182/blood.V124.21.950.950

Published: 2014

NARROW

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Transcriptional and Metabolic Profiling of Nicotinamide-Enhanced Natural Killer (NAM-NK) Cells (GDA-201)

Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Nicotinamide (NAM) Modulates Transcriptional Signature of Ex Vivo Cultured UCB CD34+ Cells (Omidubicel) and Preserves Their Stemness and Engraftment Potential

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models

Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs)

Brief Ex Vivo Incubation with Fas Ligand Selectively Depletes Alloreactive T Cells and Antigen Presenting Cells from Stem Cell Grafts

NK cell destiny after haploSCT with PT-Cy

Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma

Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-Applicable Method for NK Expansion

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only